Economic Burden

Economic Burden
Cost of Post-infusion Monitoring of Patients with LBCL Who Received Lisocabtagene Maraleucel
AMCP Nexus 2022
In patients with relapsed or refractory LBCL treated with lisocabtagene maraleucel, post-infusion monitoring costs were lower in the outpatient setting versus the inpatient setting Read More ›
Economic Burden
Economic Burden and Healthcare Resource Utilization in Patients with Relapsed or Refractory MCL
AMCP Nexus 2022
Claims-based analysis assesses healthcare resource utilization and standard-of-care costs among US patients with relapsed or refractory MCL Read More ›
Economic Burden
Out-of-Pocket Costs Incurred by Patients with Cancer: Findings from a Retrospective Claims Analysis
AMCP Nexus 2022
Medicare Advantage claims analysis explores economic burden of cancer by type and stage, underscoring the importance of early detection Read More ›

Conference Correspondent Coverage is Brought to You by the Publishers of:
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications

© Amplity Health. All Rights Reserved. Privacy Policy